Clinical Development Plan (CDP) — GLPI-103

Program-level strategic plan for GLPI-103: target product profile, unmet need, scientific rationale, competitor landscape, and the Phase 1–3 clinical development and regulatory strategy. Quantitative parameters are aligned to the canonical reconciliation in REF-002 (regulatory/_reference/clinical_program_parameters.md); where the original plan was revised for cost/realism, this is noted (see PM-003 budget rationale).

Change History

Indications under development: (1) Type 2 Diabetes Mellitus (primary); (2) Obesity; (3) Cardiometabolic disease; (4) Heart Failure with preserved Ejection Fraction (future lifecycle management).

Executive Summary

GLPI-103 is a first-in-class dual agonist of the GLP-1 receptor and the Apelin (APJ) receptor. While GLP-1 receptor agonists deliver meaningful glycaemic, weight, and cardiovascular benefit, substantial residual cardiometabolic and heart-failure risk persists in T2DM. Activation of the Apelin/APJ pathway is associated with improved insulin sensitivity, enhanced endothelial function, improved cardiac contractility, reduced inflammation, and favourable metabolic effects. GLPI-103 is designed to deliver superior glycaemic control, greater weight reduction, and improved cardiometabolic outcomes — with potential heart-failure risk reduction — beyond GLP-1 agonism alone.

1. Target Product Profile (TPP)

(Detailed TPP: regulatory/_reference/target_product_profile_TPP_v2.0.md.)

• Disease area: Type 2 Diabetes Mellitus.
• Intended population: adults with T2DM inadequately controlled on metformin; BMI ≥ 27 kg/m².
• Target claims: HbA1c reduction superior to oral semaglutide; ≥10% body-weight reduction at Week 52; cardiometabolic improvement (blood pressure, hsCRP, NT-proBNP); GI tolerability comparable to oral semaglutide.

2. Unmet Medical Need & Market Opportunity

Despite advances in GLP-1 receptor agonists, substantial unmet needs remain:

• 2.1 Inadequate glycaemic control — a significant proportion of patients fail to reach HbA1c <7.0% despite escalation.
• 2.2 Residual cardiovascular risk — cardiovascular events and heart-failure incidence remain elevated on current therapy.
• 2.3 Obesity burden — most T2DM patients have obesity / metabolic syndrome requiring substantial weight reduction.
• 2.4 Need for multifactorial therapy — current treatments focus on glucose lowering; broader cardiometabolic intervention is needed.

Epidemiology (T2DM, obesity, HFpEF prevalence) is detailed in Appendix A.

3. Scientific Rationale & Preclinical Evidence

• 3.1 GLP-1 receptor activation — increased insulin secretion, reduced glucagon, delayed gastric emptying, reduced appetite.
• 3.2 Apelin/APJ activation — enhanced insulin sensitivity, improved vascular function, increased skeletal-muscle glucose utilization, improved myocardial function.
• 3.3 Synergistic potential — the dual mechanism is expected to improve glycaemic control, enhance weight loss, and improve cardiovascular biomarkers beyond GLP-1 agonism alone.
• 3.4 Nonclinical & CMC status — see Module 4 (nonclinical) and Module 3 (quality); deep-knowledge mock where wet-lab data are not simulated.

4. Competitor Landscape

Approved products

Emerging competitors

Differentiation strategy. GLPI-103 competes through cardiometabolic positioning — heart-failure benefit potential and Apelin-mediated vascular effects — rather than solely greater weight loss.

5. Clinical Development Strategy

• 5.1 Strategic overview — staged, "fail fast / fail cheap" investment: small mechanistic Phase 1, dose-finding Phase 2 (PoC), confirmatory Phase 3.
• 5.2 Development questions — does dual GLP-1/APJ agonism deliver glycaemic superiority over a guideline comparator with acceptable tolerability, and does it improve cardiometabolic biomarkers?
• 5.3 Patient selection & biomarker strategy — T2DM on metformin; mechanistic biomarkers (plasma apelin, NT-proBNP, hsCRP, IL-6, HOMA-IR) characterized from Phase 1.
• 5.4 Lifecycle management — planned expansion to obesity, HFpEF, and cardiometabolic syndrome.
• Registration strategy — global Phase 3 program across US, EU, South Korea, Japan.

• Enrollment: ≈900 subjects (target) over ~18 months (900 randomized in the executed/simulated study; REF-002).
• Risks & mitigation: slow recruitment / disruption / high discontinuation → site expansion + digital recruitment (PM-004 risk register).
• Comparator: active-controlled vs oral semaglutide (Rybelsus).

6. Phase 1 Program Summary

• GLPI103-101 (SAD) — randomized, placebo-controlled single ascending dose; 40 healthy volunteers (5 ascending cohorts × 8; 6 active : 2 PBO). Objectives: safety, tolerability, PK, PD. No dose-limiting toxicity; dose-dependent GLP-1 activity and apelin-biomarker activation observed. Mechanistic biomarkers: plasma apelin, NT-proBNP, hsCRP, IL-6, HOMA-IR; exploratory troponin/adiponectin/leptin; imaging (echocardiography, LV mass, diastolic function) reserved for Phase 2b/3 substudy.
• GLPI103-102 (MAD) — multiple ascending dose, 40 overweight/obese adults with T2DM or prediabetes, up to 12 weeks (4 dose cohorts × 10). Results: mean HbA1c −0.8%, weight −3.1 kg.

7. Phase 2 Program Summary

• GLPI103-201 — randomized, double-blind, placebo-controlled dose-finding (PoC) in T2DM on metformin; 240 subjects (Placebo / Low / Medium / High × 60); 24 weeks; primary endpoint HbA1c CFB.

Cardiometabolic biomarkers (hsCRP, NT-proBNP, HOMA-IR) improved; common TEAEs nausea/vomiting/diarrhoea; no unexpected safety signals.

8. Phase 3 Development Plan

• GLPI103-301 — randomized, double-blind, double-dummy, active-controlled; adults with T2DM inadequately controlled on metformin. 900 randomized to target (≈300/arm).
• Arms: A GLPI-103 IV (1→2→4 mg); B GLPI-103 Oral (2→4→8 mg); C oral semaglutide (3→7→14 mg).
• Primary endpoint: HbA1c change from baseline at Week 52 (superiority vs semaglutide).
• Key secondary: weight change; HbA1c <7%; ≥10% weight reduction; NT-proBNP; hsCRP.
• Statistical framework: primary MMRM (estimand-aligned), hierarchical (fixed-sequence) multiplicity, α=0.05, power 90% (SAP-301; executed analyses in SAR-301).

9. Regulatory & Commercialization Strategy

Target submissions: FDA NDA, EMA MAA, MFDS NDA, PMDA NDA. Planned filing window Q4 2031. Regional plans and labeling: Module 1 (regulatory/m1/).

10. Clinical Operations Plan

Operational execution (monitoring, data management, randomization/IWRS, safety, pharmacy/IMP, laboratory) is detailed in the Trial Master File (tmf/); program governance/timeline/budget/vendor in PM-001–006.

11. Benefit–Risk Assessment

• Expected benefits: superior HbA1c reduction; greater weight loss; improved cardiometabolic outcomes.
• Potential risks: gastrointestinal adverse events; class-related GLP-1 toxicities.
• Conclusion: based on Phase 1–2 findings, GLPI-103 demonstrates a favourable benefit–risk profile supporting advancement into (and now completion of) Phase 3 (CSR-301; M2.5.6). (Original CDP conclusion; the executed Phase 3 confirmed superiority — SAR-301.)

Appendix

A. Epidemiology · B. Sample-size assumptions (REF-002; PM-003) · C. Biomarker plan · D. Regulatory interaction plan.